Bardet-Biedl Syndrome: A Comprehensive Review of an Autosomal Recessive Ciliopathy
Main Article Content
Abstract
Bardet-Biedl Syndrome (BBS) is a rare, genetically heterogeneous, and autosomal recessive ciliopathy characterized by a complex clinical phenotype. This article provides a comprehensive review of BBS, exploring its genetic underpinnings, clinical manifestations, molecular mechanisms, and emerging therapeutic strategies. BBS is associated with primary ciliary dysfunction, leading to a spectrum of clinical features, including obesity, retinal degeneration, renal abnormalities, polydactyly, and cognitive impairments. Understanding the intricate molecular pathways involved in BBS pathogenesis, such as the role of the BBSome and the ciliary transition zone, is crucial for developing targeted treatments. This review also discusses recent advances in the field, including the potential application of gene therapy and small molecule interventions. The aim of this article is to consolidate current knowledge on BBS, shedding light on the complexities of this rare genetic disorder and the potential avenues for future research and therapeutic development.
Article Details
This work is licensed under a Creative Commons Attribution 4.0 International License.
References
I. Klein D, Ammann F. The syndrome of Laurence-Moon-Bardet-Biedl and allied diseases in Switzerland. J Neurol Sci. 1969;9(3):479–513. doi:10.1016/0022-510X(69)90091-4
II. Beales PL, Warner AM, Hitman GA, Thakker R, Flinter FA. Bardet-Biedl syndrome: a molecular and phenotypic study of 18 families. J Med Genet. 1997;34(2):92–98. doi:10.1136/jmg.34.2.92
III. Farag TI, Teebi AS. High incidence of Bardet Biedl syndrome among the Bedouin. Clin Genet. 1989;36(6):463–464. doi:10.1111/j.1399-0004.1989.tb03378.x
IV. Moore SJ, Green JS, Fan Y, et al. Clinical and genetic epidemiology of Bardet-Biedl syndrome in newfoundland: a 22-year prospective, population-based, cohort study. Am J Med Genet A. 2005;132A(4):352–360. doi:10.1002/ajmg.a.30406
V. Hjortshøj TD, Grønskov K, Brøndum-Nielsen K, Rosenberg T. A novel founder BBS1 mutation explains a unique high prevalence of Bardet-Biedl syndrome in the Faroe Islands. Br J Ophthalmol. 2009;93(3):409–413. doi:10.1136/bjo.2007.131110
VI. Turkyilmaz A, Geckinli BB, Alavanda C, et al. Meckel-Gruber syndrome: clinical and molecular genetic profiles in two fetuses and review of the current literature. Genet Test Mol Biomarkers. 2021;25(6):445–451. doi:10.1089/gtmb.2020.0311
VII. Reiter JF, Leroux MR. Genes and molecular pathways underpinning ciliopathies. Nat Rev Mol Cell Biol. 2017;18(9):533–547. doi:10.1038/nrm.2017.60
VIII. Estrada-Cuzcano A, Roepman R, Cremers FPM, den Hollander AI, Mans DA. Non-syndromic retinal ciliopathies: translating gene discovery into therapy. Hum Mol Genet. 2012;21(R1):R111–R124. doi:10.1093/hmg/dds298
IX. Gupta N, D’Acierno M, Zona E, Capasso G, Zacchia M. Bardet-Biedl syndrome: the pleiotropic role of the chaperonin-like BBS6, 10, and 12 proteins. Am J Med Genet C Semin Med Genet. 2022;190(1):9–19. doi:10.1002/ajmg.c.31970
X. Ishikawa H, Thompson J, Yates JR, Marshall WF. Proteomic analysis of mammalian primary cilia. Curr Biol. 2012;22(5):414–419. doi:10.1016/j.cub.2012.01.031
XI. Zacchia M, Marchese E, Trani EM, et al. Proteomics and metabolomics studies exploring the pathophysiology of renal dysfunction in autosomal dominant polycystic kidney disease and other ciliopathies. Nephrol Dial Transplant. 2019:gfz121. doi:10.1093/ndt/gfz121
XII. Long H, Huang K. Transport of ciliary membrane proteins. Front Cell Dev Biol. 2019;7:381. doi:10.3389/fcell.2019.00381
XIII. Beales PL, Elcioglu N, Woolf AS, Parker D, Flinter FA. New criteria for improved diagnosis of Bardet-Biedl syndrome: results of a population survey. J Med Genet. 1999;36(6):437–446. doi:10.1136/jmg.36.6.437